Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity

Author： Blomström-Lundqvist Carina   Blomström Per  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.11, Iss.4, 2012-07, pp. : 671-679

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spotlight on Intravenous Vernakalant in Recent-Onset Atrial Fibrillation†

By Duggan Sean T.   Scott Lesley J.  

Drugs & Aging, Vol. 28, Iss. 6, 2011-06 ,pp. : 501-504

Adis International

Access to resources Recommend Favorite

Predictors of Successful Cardioversion with Vernakalant in Patients with Recent-Onset Atrial Fibrillation

By Mochalina Natalia   Juhlin Tord   Öhlin Bertil   Carlson Jonas   Holmqvist Fredrik   Platonov Pyotr G.  

Annals of Noninvasive Electrocardiology, Vol. 20, Iss. 2, 2015-03 ,pp. : 140-147

Blackwell Publishing

Access to resources Recommend Favorite

New antiarrhythmic agents for atrial fibrillation and atrial flutter

By Pecini Redi   Elming Hanne   Pedersen Ole Dyg   Torp-Pedersen Christian  

Expert Opinion on Emerging Drugs, Vol. 10, Iss. 2, 2005-05 ,pp. : 311-322

Informa Healthcare

Access to resources Recommend Favorite

Vernakalant for the Conversion of Atrial Fibrillation: The New Kid On the Block?

By Conde Diego   Baranchuk Adrian  

Annals of Noninvasive Electrocardiology, Vol. 19, Iss. 4, 2014-07 ,pp. : 299-302

Blackwell Publishing

Access to resources Recommend Favorite

Intravenous vernakalant: a guide to its use in recent-onset atrial fibrillation

By  

Drugs & Therapy Perspectives, Vol. 27, Iss. 8, 2011-08 ,pp. : 6-10

Adis International

Access to resources Recommend Favorite